Your browser doesn't support javascript.
Epidemiologic Characteristics Associated With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antigen-Based Test Results, Real-Time Reverse Transcription Polymerase Chain Reaction (rRT-PCR) Cycle Threshold Values, Subgenomic RNA, and Viral Culture Results From University Testing.
Ford, Laura; Lee, Christine; Pray, Ian W; Cole, Devlin; Bigouette, John Paul; Abedi, Glen R; Bushman, Dena; Delahoy, Miranda J; Currie, Dustin W; Cherney, Blake; Kirby, Marie K; Fajardo, Geroncio C; Caudill, Motria; Langolf, Kimberly; Kahrs, Juliana; Zochert, Tara; Kelly, Patrick; Pitts, Collin; Lim, Ailam; Aulik, Nicole; Tamin, Azaibi; Harcourt, Jennifer L; Queen, Krista; Zhang, Jing; Whitaker, Brett; Browne, Hannah; Medrzycki, Magdalena; Shewmaker, Patricia L; Bonenfant, Gaston; Zhou, Bin; Folster, Jennifer M; Bankamp, Bettina; Bowen, Michael D; Thornburg, Natalie J; Goffard, Kimberly; Limbago, Brandi; Bateman, Allen; Tate, Jacqueline E; Gieryn, Douglas; Kirking, Hannah L; Westergaard, Ryan P; Killerby, Marie E.
  • Ford L; COVID-19 Response Team, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, USA.
  • Lee C; Epidemic Intelligence Service, CDC, Atlanta, Georgia, USA.
  • Pray IW; COVID-19 Response Team, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, USA.
  • Cole D; Laboratory Leadership Service, CDC, Atlanta, Georgia, USA.
  • Bigouette JP; COVID-19 Response Team, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, USA.
  • Abedi GR; Epidemic Intelligence Service, CDC, Atlanta, Georgia, USA.
  • Bushman D; Wisconsin Department of Health Services, Madison, Wisconsin, USA.
  • Delahoy MJ; Wisconsin Department of Health Services, Madison, Wisconsin, USA.
  • Currie DW; School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, USA.
  • Cherney B; COVID-19 Response Team, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, USA.
  • Kirby MK; Epidemic Intelligence Service, CDC, Atlanta, Georgia, USA.
  • Fajardo GC; COVID-19 Response Team, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, USA.
  • Caudill M; COVID-19 Response Team, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, USA.
  • Langolf K; Epidemic Intelligence Service, CDC, Atlanta, Georgia, USA.
  • Kahrs J; COVID-19 Response Team, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, USA.
  • Zochert T; Epidemic Intelligence Service, CDC, Atlanta, Georgia, USA.
  • Kelly P; COVID-19 Response Team, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, USA.
  • Pitts C; Epidemic Intelligence Service, CDC, Atlanta, Georgia, USA.
  • Lim A; COVID-19 Response Team, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, USA.
  • Aulik N; COVID-19 Response Team, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, USA.
  • Tamin A; COVID-19 Response Team, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, USA.
  • Harcourt JL; COVID-19 Response Team, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, USA.
  • Queen K; Agency for Toxic Substances and Disease Registry, CDC, Atlanta, Georgia, USA.
  • Zhang J; University of Wisconsin-Oshkosh, Oshkosh, Wisconsin, USA.
  • Whitaker B; University of Wisconsin-Oshkosh, Oshkosh, Wisconsin, USA.
  • Browne H; University of Wisconsin-Oshkosh, Oshkosh, Wisconsin, USA.
  • Medrzycki M; University Health Services, University of Wisconsin-Madison, Madison, Wisconsin, USA.
  • Shewmaker PL; School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, USA.
  • Bonenfant G; University Health Services, University of Wisconsin-Madison, Madison, Wisconsin, USA.
  • Zhou B; Wisconsin Veterinary Diagnostic Laboratory University of Wisconsin-Madison, Madison, Wisconsin, USA.
  • Folster JM; Wisconsin Veterinary Diagnostic Laboratory University of Wisconsin-Madison, Madison, Wisconsin, USA.
  • Bankamp B; COVID-19 Response Team, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, USA.
  • Bowen MD; COVID-19 Response Team, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, USA.
  • Thornburg NJ; COVID-19 Response Team, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, USA.
  • Goffard K; COVID-19 Response Team, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, USA.
  • Limbago B; COVID-19 Response Team, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, USA.
  • Bateman A; COVID-19 Response Team, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, USA.
  • Tate JE; COVID-19 Response Team, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, USA.
  • Gieryn D; COVID-19 Response Team, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, USA.
  • Kirking HL; COVID-19 Response Team, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, USA.
  • Westergaard RP; COVID-19 Response Team, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, USA.
  • Killerby ME; COVID-19 Response Team, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, USA.
Clin Infect Dis ; 73(6): e1348-e1355, 2021 09 15.
Article in English | MEDLINE | ID: covidwho-1479943
ABSTRACT

BACKGROUND:

Real-time reverse transcription polymerase chain reaction (rRT-PCR) and antigen tests are important diagnostics for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Sensitivity of antigen tests has been shown to be lower than that of rRT-PCR; however, data to evaluate epidemiologic characteristics that affect test performance are limited.

METHODS:

Paired mid-turbinate nasal swabs were collected from university students and staff and tested for SARS-CoV-2 using both Quidel Sofia SARS Antigen Fluorescent Immunoassay (FIA) and rRT-PCR assay. Specimens positive by either rRT-PCR or antigen FIA were placed in viral culture and tested for subgenomic RNA (sgRNA). Logistic regression models were used to evaluate characteristics associated with antigen results, rRT-PCR cycle threshold (Ct) values, sgRNA, and viral culture.

RESULTS:

Antigen FIA sensitivity was 78.9% and 43.8% among symptomatic and asymptomatic participants, respectively. Among rRT-PCR positive participants, negative antigen results were more likely among asymptomatic participants (odds ratio [OR] 4.6, 95% confidence interval [CI] 1.3-15.4) and less likely among participants reporting nasal congestion (OR 0.1, 95% CI .03-.8). rRT-PCR-positive specimens with higher Ct values (OR 0.5, 95% CI .4-.8) were less likely, and specimens positive for sgRNA (OR 10.2, 95% CI 1.6-65.0) more likely, to yield positive virus isolation. Antigen testing was >90% positive in specimens with Ct values < 29. Positive predictive value of antigen test for positive viral culture (57.7%) was similar to that of rRT-PCR (59.3%).

CONCLUSIONS:

SARS-CoV-2 antigen test advantages include low cost, wide availability and rapid turnaround time, making them important screening tests. The performance of antigen tests may vary with patient characteristics, so performance characteristics should be accounted for when designing testing strategies and interpreting results.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Diagnostic study / Experimental Studies / Observational study / Prognostic study Limits: Humans Language: English Journal: Clin Infect Dis Journal subject: Communicable Diseases Year: 2021 Document Type: Article Affiliation country: Cid

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Diagnostic study / Experimental Studies / Observational study / Prognostic study Limits: Humans Language: English Journal: Clin Infect Dis Journal subject: Communicable Diseases Year: 2021 Document Type: Article Affiliation country: Cid